Anticancer research · 2012
Efficacy and feasibility of induction chemotherapy and radiotherapy plus cetuximab in head and neck cancer.
Клиническое исследование II фазыСтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rampino M, Bacigalupo A, Russi E, Schena M, Lastrucci L, Iotti C, Reali A, Musu A, Balcet V, Piva C, Bustreo S, Munoz F, Ragona R, Corvò R, Ricardi U
Аннотация
BACKGROUND: To determine the potential activity and tolerability of sequential treatment in head and neck cancer, we conducted a phase II trial based on induction chemotherapy of two cycles of taxotere, cisplatin and 5-fluorouracil followed by radiotherapy plus weekly cetuximab.
PATIENTS AND METHODS: Thirty-six patients with stage III or IV squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx were treated and evaluated for response and acute toxicity.
RESULTS: Eighty-one percent of patients had stage IV disease and 42% had hypopharyngeal and oral cavity primaries. The overall response rate was 81.8%, with 60.6% complete response and 33.3% partial response. Severe toxicities were febrile neutropenia (6%) during induction chemotherapy and dermatitis (48%), mucositis (33%) and dysphagia (12%) during the concurrent phase.
CONCLUSION: Our protocol proved to be feasible, effective and well tolerated. This sequential strategy should be further investigated.
PATIENTS AND METHODS: Thirty-six patients with stage III or IV squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx were treated and evaluated for response and acute toxicity.
RESULTS: Eighty-one percent of patients had stage IV disease and 42% had hypopharyngeal and oral cavity primaries. The overall response rate was 81.8%, with 60.6% complete response and 33.3% partial response. Severe toxicities were febrile neutropenia (6%) during induction chemotherapy and dermatitis (48%), mucositis (33%) and dysphagia (12%) during the concurrent phase.
CONCLUSION: Our protocol proved to be feasible, effective and well tolerated. This sequential strategy should be further investigated.
Предметные рубрики MeSH
AgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBridged-Ring CompoundsCarcinoma, Squamous CellCetuximabChemoradiotherapyCisplatinFeasibility StudiesFemaleFluorouracilFollow-Up StudiesHead and Neck NeoplasmsHumansInduction ChemotherapyMaleMaximum Tolerated DoseMiddle AgedNeoplasm StagingRemission InductionSurvival RateTaxoidsTreatment Outcome